Showing 4891-4900 of 8126 results for "".
- FDA Approves Regeneron's Libtayo, First Treatment for Metastatic or Locally Advanced SCChttps://practicaldermatology.com/news/fda-approves-regenerons-libtayo-first-treatment-for-metastatic-or-locally-advanced-scc/2457589/Libtayo (cemiplimab-rwlc) injection (Regeneron Pharmaceuticals, Inc.) is now FDA-approved for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiatio
- RealSelf Survey: More than 1 in 3 US Adults are Considering Nips/Tuckshttps://practicaldermatology.com/news/realself-survey-more-than-1-in-3-us-adults-are-considering-nipstucks/2457591/One in three adults (37 percent) in the US are considering at least one cosmetic treatment in the next 12 months, with significantly more considering nonsurgical procedures (34 percent) than surgical ones (24 percent), according to the
- Candela and Vascular Birthmark Foundation Offer Pro Bono Laser Treatments for Patients in Needhttps://practicaldermatology.com/news/candela-and-vascular-birthmark-foundation-offer-pro-bono-laser-treatments-for-patients-in-need/2457593/Candela Corporation is partnering with the Vascular Birthmarks Foundation (VBF) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related skin conditions as a kickoff to the VBF 18th A
- With Launch of TruSculpt ID, Cutera Defines Today's Body Contouring Patienthttps://practicaldermatology.com/news/with-launch-of-trusculpt-id-cutera-defines-todays-body-contouring-patient/2457594/A third of Americans opt for body sculpting treatments to look better naked, according to a new survey from Cutera, Inc. The survey results were released to coincide with the availability of truSculpt iD, a non-
- FDA Clears Sebacia Microparticles for Laser-Based Acne Treatmenthttps://practicaldermatology.com/news/fda-clears-sebacia-microparticles-for-laser-based-acne-treatment/2457603/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic
- Allergan Launches Spotlyte: Digital Hub Will Educate Consumers About Medical Aesthetic Treatmentshttps://practicaldermatology.com/news/allergan-launches-spotlyte/2457615/Allergan has launched Spotlyte, described as an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines.
- New Laser Handpiece Clears Multicolor Tattoos in Fewer Treatmentshttps://practicaldermatology.com/news/new-laser-handpiece-clears-multicolor-tattoos-in-fewer-treatments/2457613/A new titanium sapphire laser handpiece can clear green, blue, and purple tattoo pigments in fewer treatments, according to a new study in Lasers in Surgery and Medicine (LSM). Researchers led by American Soc
- Foamix: Positive Topline Phase 3 Results for Topical Minocycline Foamhttps://practicaldermatology.com/news/foamix-positive-topline-phase-3-results-for-topical-minocycline-foam/2457614/Foamix Pharmaceuticals’ FMX101 topical minocycline foam for the treatment of moderate-to-severe acne has met primary endpoints of its third Phase 3 clinical trial. Foamix shared topline results of the clinical trial (FX2017-22), which met both co-prim
- Allergan's SkinMedica Tackles Blue Light and More with New LUMIVIVE Systemhttps://practicaldermatology.com/news/skinmedica-tackles-blue-light-and-more-with-new-lumivie-system/2457620/Allergan is launching the SkinMedica LUMIVIVE System, with two distinct formulas - one to shield skin from blue light and environmental aggressors during the day and another to recharge the skin's repair process at night for 24-hour protection and revital
- Bee Venom May Help Treat Eczemahttps://practicaldermatology.com/news/bee-venom-may-help-treat-eczema/2457619/Bee venom and its major component, melittin, may be effective treatments for atopic dermatitis, according to a British Journal of Pharmacology study. Through studies conducted in mice and in human cells, inv